Fundraising Fox
Maxona Pharmaceuticals
Malvern, US · Founded 2016 · Delaware corporation
Find your way into Maxona Pharmaceuticals
Sign up to see every warm intro you have to Maxona Pharmaceuticals
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Maxona Pharmaceuticals team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
MAXONA Pharmaceuticals develops non-opioid pain treatment options for the U.S. market. The company is focused on expanding therapeutic alternatives in pain management.
Founders & leadership
SF
Shahin FatholahiExecutive
RB
Richard BrandConsultantRichard Brand is an executive officer at Maxona Pharmaceuticals with extensive experience in biotech finance and operations. He previously served as CFO at multiple biotech companies, including one that completed a strong IPO in 2017 and another that raised $86 million in Series B funding, and has worked in liquid biopsy diagnostics and public company investor relations.
SF
Shawn FatholahiPresident & CEOHe holds an MBA and BS in Biology, and brings commercial pharmaceutical experience including product launches, marketing strategy, and alliance management across multiple therapeutic areas.
Board
DN
David NakamuraBoard director
BS
Behshad SheldonBoard director
Reported raises · per SEC filings
Form D private placements$11.3M disclosed across 2 rounds · 2021–2025
▶$5.8MraisedAug 2026 · 56 investors · PharmaceuticalsRule 506(b)
▶$5.8MraisedAug 2026 · 56 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Shahin FatholahiExecutive Officer, Director
- Behshad SheldonDirector
- David NakamuraDirector
- Richard BrandExecutive Officer
- Offering amount
- $12M
- Amount sold
- $5.8M
- Sales commissions
- $412.1K
- Proceeds to insiders
- $1M
- Placement agents
- Arcadia Securities, LLC
- First sale
- Jun 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.6MraisedMay 2021 · 34 investors · PharmaceuticalsRule 506(b)
▶$5.6MraisedMay 2021 · 34 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- David NakamuraDirector
- Behshad SheldonDirector
- Shahin FatholahiExecutive Officer, Director
- Offering amount
- $10M
- Amount sold
- $5.6M
- Sales commissions
- $502.2K
- Placement agents
- Arcadia Securities, LLC
- First sale
- Apr 2021
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Maxona Pharmaceuticals do?
- MAXONA Pharmaceuticals develops non-opioid pain treatment options for the U.S. market. The company is focused on expanding therapeutic alternatives in pain management.
- How much funding has Maxona Pharmaceuticals raised?
- Maxona Pharmaceuticals has disclosed $11.3M raised across 2 rounds.
- Where is Maxona Pharmaceuticals headquartered?
- Maxona Pharmaceuticals is headquartered in Malvern, US.